Events

In April 2022, we discussed the role of molecular testing platforms, such as qPCR, ddPCR and NGS in enabling discovery and development of cell and gene therapy products. These technologies were recently introduced to bioanalysis of cell and gene therapy products, resulting in many unanswered questions on the appropriate use of these technologies in the field of bioanalysis, especially due to the lack of prescriptive guidance. We will use a redacted and anonymized qPCR case study to answer some of the questions that frequently come up.

In April 2022, we discussed the role of molecular testing platforms, such as qPCR, ddPCR and NGS in enabling discovery and development of cell and gene therapy products. These technologies were recently introduced to bioanalysis of cell and gene therapy products, resulting in many unanswered questions on the appropriate use of these technologies in the field of bioanalysis, especially due to the lack of prescriptive guidance. We will use a redacted and anonymized qPCR case study to answer some of the questions that frequently come up.

In April 2022, we discussed the role of molecular testing platforms, such as qPCR, ddPCR and NGS in enabling discovery and development of cell and gene therapy products. These technologies were recently introduced to bioanalysis of cell and gene therapy products, resulting in many unanswered questions on the appropriate use of these technologies in the field of bioanalysis, especially due to the lack of prescriptive guidance. We will use a redacted and anonymized qPCR case study to answer some of the questions that frequently come up.

Join us for the demonstration of the prototype of an automated software tool for determining cut point using Random Effects Model. Additionally, Dr. Stephanie Pasas-Farmer will be presenting at Bioassay Summit as well as co-presenting with Dr. Cheikh Kane from KCAS at Immunogenicity Summit.

In April 2022, we discussed the role of molecular testing platforms, such as qPCR, ddPCR and NGS in enabling discovery and development of cell and gene therapy products. These technologies were recently introduced to bioanalysis of cell and gene therapy products, resulting in many unanswered questions on the appropriate use of these technologies in the field of bioanalysis, especially due to the lack of prescriptive guidance. We will use a redacted and anonymized qPCR case study to answer some of the questions that frequently come up.